Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.

Demir N, Kıkılı Cİ, Kemik F, Köylü B, Tural D, Laçin Ş, Gündüz Ş, Tunalı D, Mandel NM, Yumuk F, Inanc M, Cengiz AN, Uluç BO, Ersoy SA, Busery NS, Karakaya S, Erdem D, Akdoğan O, Yazıcı O, Kahraman E, Bilgetekin İ, Demirci U, Gür HB, Ökten İN, Karakaya G, Yıldız O, Eryılmaz MK, Canaslan K, Seyyar M, Kaplan MA, Çubukçu E, Akın G, Ersoy M, Sümbül AT, Özçelik H, Özel Bozdağ Dİ, Çiçek E, Oflas Ü, Turkoz FP, Garbioğlu DB, Selçukbiricik F

Open source

DOI
10.1016/j.lungcan.2026.109590
Published
2026 Oct
Container
Lung cancer (Amsterdam, Netherlands)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2026.109590,
  title = {Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.},
  author = {Demir N and Kıkılı Cİ and Kemik F and Köylü B and Tural D and Laçin Ş and Gündüz Ş and Tunalı D and Mandel NM and Yumuk F and Inanc M and Cengiz AN and Uluç BO and Ersoy SA and Busery NS and Karakaya S and Erdem D and Akdoğan O and Yazıcı O and Kahraman E and Bilgetekin İ and Demirci U and Gür HB and Ökten İN and Karakaya G and Yıldız O and Eryılmaz MK and Canaslan K and Seyyar M and Kaplan MA and Çubukçu E and Akın G and Ersoy M and Sümbül AT and Özçelik H and Özel Bozdağ Dİ and Çiçek E and Oflas Ü and Turkoz FP and Garbioğlu DB and Selçukbiricik F},
  year = {2026},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2026.109590},
  url = {https://doi.org/10.1016/j.lungcan.2026.109590}
}

RIS

TY  - JOUR
TI  - Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.
AU  - Demir N
AU  - Kıkılı Cİ
AU  - Kemik F
AU  - Köylü B
AU  - Tural D
AU  - Laçin Ş
AU  - Gündüz Ş
AU  - Tunalı D
AU  - Mandel NM
AU  - Yumuk F
AU  - Inanc M
AU  - Cengiz AN
AU  - Uluç BO
AU  - Ersoy SA
AU  - Busery NS
AU  - Karakaya S
AU  - Erdem D
AU  - Akdoğan O
AU  - Yazıcı O
AU  - Kahraman E
AU  - Bilgetekin İ
AU  - Demirci U
AU  - Gür HB
AU  - Ökten İN
AU  - Karakaya G
AU  - Yıldız O
AU  - Eryılmaz MK
AU  - Canaslan K
AU  - Seyyar M
AU  - Kaplan MA
AU  - Çubukçu E
AU  - Akın G
AU  - Ersoy M
AU  - Sümbül AT
AU  - Özçelik H
AU  - Özel Bozdağ Dİ
AU  - Çiçek E
AU  - Oflas Ü
AU  - Turkoz FP
AU  - Garbioğlu DB
AU  - Selçukbiricik F
PY  - 2026
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2026.109590
UR  - https://doi.org/10.1016/j.lungcan.2026.109590
ER  -

APA

N, D., Cİ, K., F, K., B, K., D, T., Ş, L., Ş, G., D, T., NM, M., F, Y., M, I., AN, C., BO, U., SA, E., NS, B., S, K., D, E., O, A., O, Y., E, K., İ, B., U, D., HB, G., İN, Ö., G, K., O, Y., MK, E., K, C., M, S., MA, K., E, Ç., G, A., M, E., AT, S., H, Ö., Dİ, Ö. B., E, Ç., Ü, O., FP, T., DB, G., & F, S. (2026). Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2026.109590

Source records